Oncology

Back to articles

Pazopanib for advanced renal cell carcinoma

KEY POINT

Results from a Phase III trial showed that treatment with pazopanib (Votrient—GlaxoSmithKline) 800 mg once daily significantly improved progressionfree survival (PFS) and tumor response compared with placebo in both treatmentnaive and cytokine-pretreated patients with clear cell advanced renal cell carcinoma.